GCP
OKUR

GSA Capital Partners’s OnKure Therapeutics OKUR Stock Holding History

GSA Capital Partners’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,224
Closed -$92K – 2255
2026
Q1 		$92K Sell
22,224
-23,724
-52% -$73.2K 0.01% 1566
2025
Q4 		$133K Sell
45,948
-13,276
-22% -$39.7K 0.01% 1496
2025
Q3 		$163K Buy
59,224
+37,459
+172% +$92.8K 0.01% 1469
2025
Q2 		$52K Buy
+21,765
New +$57.1K ﹤0.01% 1660
2024
Q2 		– Sell
-8,802
Closed -$146K – 2092
2024
Q1 		$146K Sell
8,802
-685
-7% -$11.3K 0.01% 1453
2023
Q4 		$152K Buy
+9,487
New +$591K 0.01% 1367

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSA Capital Partners's OKUR Position: Q2 2026 in Review

GSA Capital Partners sold out of OnKure Therapeutics (OKUR) in Q2 2026, closing a stake of 22,224 shares — an estimated $92K sold.

GSA Capital Partners first reported a position in OKUR in Q4 2023 and held it in 6 quarters. The position peaked at $163K in Q3 2025. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • GSA Capital Partners reported no remaining OnKure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 22,224 OnKure Therapeutics shares in Q2 2026, an estimated $92K.
  • GSA Capital Partners first reported a position in OnKure Therapeutics in Q4 2023 and held it in 6 quarters.
  • GSA Capital Partners's OnKure Therapeutics position peaked at $163K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.